OrganiGram’s (OGI) Outperform Rating Reaffirmed at Raymond James

OrganiGram (TSE:OGI)‘s stock had its “outperform” rating restated by equities research analysts at Raymond James in a research report issued on Wednesday, Stock Target Advisor reports. They presently have a C$5.00 target price on the stock. Raymond James’ price objective would suggest a potential upside of 65.56% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Atb Cap Markets restated a “sector perform” rating on shares of OrganiGram in a research report on Friday, July 23rd. CIBC lifted their price objective on OrganiGram from C$3.75 to C$4.00 in a research report on Wednesday, July 14th. Jefferies Financial Group upped their target price on OrganiGram from C$3.57 to C$3.83 in a research report on Friday, September 3rd. Finally, ATB Capital lifted their target price on OrganiGram from C$3.75 to C$4.25 and gave the stock a “na” rating in a report on Wednesday, July 14th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, OrganiGram has an average rating of “Hold” and a consensus target price of C$4.11.

Shares of OGI stock traded down C$0.02 during trading hours on Wednesday, hitting C$3.02. 994,980 shares of the company’s stock traded hands, compared to its average volume of 3,012,632. The stock has a market cap of C$902.32 million and a PE ratio of -4.84. The stock’s 50 day simple moving average is C$3.26 and its 200 day simple moving average is C$3.57. The company has a quick ratio of 10.99, a current ratio of 13.70 and a debt-to-equity ratio of 1.23. OrganiGram has a 12 month low of C$1.35 and a 12 month high of C$8.00.

OrganiGram (TSE:OGI) last posted its quarterly earnings data on Tuesday, July 13th. The company reported C($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of C($0.04) by C$0.01. The company had revenue of C$20.32 million during the quarter, compared to analyst estimates of C$17.41 million. As a group, equities research analysts expect that OrganiGram will post -0.11 EPS for the current fiscal year.

About OrganiGram

Organigram Holdings Inc, through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co, ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market.

Featured Story: Cost of Capital

Stock Target Advisor logo

Analyst Recommendations for OrganiGram (TSE:OGI)

Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with's FREE daily email newsletter.